Camille L Bedrosian Amylyx Pharmaceuticals, Inc. (AMLX) insider trading activity

Camille L Bedrosian is Chief Medical Officer of Amylyx Pharmaceuticals, Inc.. Currently has a direct ownership of 175,756 shares of AMLX, which is worth approximately $2.23 Million. The most recent transaction as insider was on Dec 01, 2025, when has been sold 6,580 shares (Common Stock) at a price of $14.35 per share, resulting in proceeds of $94,423. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 176K

3.61% 3M change

27.01% 12M change

Total Value Held $2.23 Million

Camille L Bedrosian Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 01 2025	SELL Open market or private sale	$94,423 $14.35 p/Share	6,580 Reduced 3.61%	175,756 Common Stock
Sep 30 2025	SELL Open market or private sale	$175,528 $14.58 p/Share	12,039 Reduced 6.19%	182,336 Common Stock
Mar 31 2025	SELL Open market or private sale	$43,114 $3.47 p/Share	12,425 Reduced 6.01%	194,375 Common Stock
Mar 06 2025	BUY Grant, award, or other acquisition	-	68,420 Added 24.86%	206,800 Common Stock
Dec 02 2024	SELL Open market or private sale	$30,032 $5.54 p/Share	5,421 Reduced 3.77%	138,380 Common Stock
Sep 30 2024	SELL Open market or private sale	$36,614 $3.2 p/Share	11,442 Reduced 7.37%	143,801 Common Stock
Apr 16 2024	BUY Grant, award, or other acquisition	-	96,910 Added 38.43%	155,243 Common Stock

Nov 27 2023	BUY Grant, award, or other acquisition	-	58,333 Added 50.0%	58,333 Common Stock

Also insider at

CRNX

Crinetics Pharmaceuticals, Inc. Healthcare

RARE

Ultragenyx Pharmaceutical Inc. Healthcare

EVP and Chief Medical Officer

RYTM

RHYTHM PHARMACEUTICALS, INC. Healthcare

Director

CLB